跳至主要内容
临床试验/NCT07001163
NCT07001163已完成不适用

Assessment of the Role of Probiotics in Prevention of Ventilator-Associated Pneumonia in Neonates

Lamiaa Khaled Zidan1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2023年5月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
80
试验地点
1
主要终点
VAP incidence rate

研究概览

简要总结

Evaluate the preventive value of probiotics on VAP among ventilated neonates.

详细描述

MV is a critical component of neonatal intensive care, providing essential respiratory support for neonates with severe respiratory distress. However, its use is associated with an increased risk of VAP, a serious nosocomial lung infection. VAP is defined as a pneumonia diagnosed in patients undergoing MV for at least 48 hours and is recognized as the second most common nosocomial infection in neonatal and pediatric intensive care units. Its incidence ranges from 1 to 63 episodes per 1,000 ventilation days, with variability influenced by the socioeconomic and healthcare development of different regions.Given the complex pathophysiology of VAP, numerous prevention strategies have been proposed for NICUs.Among these strategies, probiotics have emerged.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
1 Day 至 28 Days(Child)
性别
All
接受健康志愿者
否

入选标准

  • •All term neonates who required mechanical ventilation with ETT for more than 48 hours.

排除标准

  • •Early-onset neonatal sepsis
  • •Pre-existing pneumonia
  • •A patient who was unfit for enteral intake.
  • •Prematurity <37 gestational weeks.
  • •Surgical causes of mechanical ventilation
  • •Multiple congenital anomalies and suspected chromosomal anomalies.

研究组 & 干预措施

Non-probiotic group

No Intervention

40 ventilated neonates who only received the standard of care treatment

Probiotic group

Active Comparator

40 ventilated neonates who received commercially available probiotics

干预措施: Probiotic (Dietary Supplement)

结局指标

主要结局

VAP incidence rate

时间窗: one year

Evaluation of the role of probiotics in the Prevention of neonatal VAP and examining their impact on the incidence of VAP at those neonates.

次要结局

  • GIT manifestations(one year)
  • Duration of MV and NICU stay(one year)

研究者

发起方
Lamiaa Khaled Zidan
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Lamiaa Khaled Zidan

Lecturer

Tanta University

研究点 (1)

Loading locations...

相似试验

Assessment of the Role of Probiotics in Prevention... | 临床试验